Duration of androgen suppression before radiotherapy for localized prostate cancer: radiation therapy oncology group randomized clinical trial 9910

What Was Tested

This randomized controlled trial paper looks at Leuprolide and Goserelin.

Who Took Part

The age groups tagged for this paper are middle-aged adults, older adults and people over 80, men only.

One thousand five hundred seventy-nine men with intermediate-risk prostate cancer were randomly assigned to 8 weeks of AS followed by radiotherapy with an additional 8 weeks of concurrent AS (16 weeks total) or to 28 weeks of AS followed by radiotherapy with an additional 8 weeks of AS (36 weeks total).

How the Study Was Run

The researchers set it up as a randomized study.

Because people in this Leuprolide study were split into groups at random, differences between the groups are less likely to reflect who happened to join each one.

The timeline in the abstract includes 10 years.

Time-to-event end points are reported for up to 10 years of follow-up.

What Was Measured

Topics PubMed links to this paper include Androgen Antagonists, Anilides, Antineoplastic Agents, Hormonal, Antineoplastic Combined Chemotherapy Protocols, Chemoradiotherapy, Disease-Free Survival and Flutamide.

What This Means in Plain Language

The paper is a randomized study of Leuprolide and Goserelin over 10 years.

Its findings take up roughly 6 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 2015 (Journal of clinical oncology : official journal of the American Society of Clinical Oncology), a journal based in United States.

More context: the Leuprolide compound page and the Goserelin compound page.